Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ all treated with imatinib containing regimen: preliminary report of two cases. [electronic resource]
Producer: 20070130Description: 321-4 p. digitalISSN:- 0392-9078
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Benzamides
- Drug Monitoring
- Female
- Fusion Proteins, bcr-abl -- genetics
- Gene Rearrangement -- genetics
- Humans
- Imatinib Mesylate
- Immunoglobulin J-Chains -- genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Piperazines -- therapeutic use
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Pyrimidines -- therapeutic use
- RNA, Neoplasm -- genetics
- Reverse Transcriptase Polymerase Chain Reaction
- WT1 Proteins -- genetics
No physical items for this record
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.